Enhancing Neural Transmission in Multiple Sclerosis (4-Aminopyridine Therapy)
- 1 January 2013
- journal article
- review article
- Published by Elsevier BV in Neurotherapeutics
- Vol. 10 (1), 106-110
- https://doi.org/10.1007/s13311-012-0156-3
Abstract
No abstract availableKeywords
This publication has 38 references indexed in Scilit:
- Single‐Dose Pharmacokinetics of Sustained‐Release Fampridine (Fampridine‐SR) in Healthy Volunteers and Adults With Renal ImpairmentThe Journal of Clinical Pharmacology, 2010
- Aminopyridines Potentiate Synaptic and Neuromuscular Transmission by Targeting the Voltage-activated Calcium Channel β SubunitOnline Journal of Public Health Informatics, 2009
- Contribution of impaired mobility to patient burden in multiple sclerosisCurrent Medical Research and Opinion, 2009
- Dose comparison trial of sustained-release fampridine in multiple sclerosisNeurology, 2008
- Shaker‐type potassium channel subunits differentially control oligodendrocyte progenitor proliferationGlia, 2004
- 4-Aminopyridine in Chronic Spinal Cord Injury: A Controlled, Double-Blind, Crossover Study in Eight PatientsJournal of Neurotrauma, 1993
- The effect of 4‐aminopyridine on clinical signs in multiple sclerosis: A randomized, placebo‐controlled, double‐blind, cross‐over studyAnnals of Neurology, 1992
- Physiological effects of 4‐aminopyridine on demyelinated mammalian motor and sensory fibersAnnals of Neurology, 1987
- Voltage-gated potassium channels are required for human T lymphocyte activation.The Journal of Experimental Medicine, 1984
- Effects of 4-Aminopyridine in Elderly Patients with Alzheimer’s DiseaseThe New England Journal of Medicine, 1984